Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma

Stock News06-14 18:20

Genscript Biotech (ASX: 01548) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

The data were presented at a late-breaking session of the 2026 European Hematology Association Congress. In the ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion.

At the higher dose level, the therapy demonstrated a 100% objective response rate and an 83.3% complete response rate among evaluable patients, with all responses ongoing at the time of data analysis.

LB2501 also exhibited a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133005411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-14 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133005411","market":"sg","top_or_hot":-1,"title":"Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma","media":"Stock News","content":"<p><b>Genscript Biotech</b> (<b>ASX: 01548</b>) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br><br>The data were presented at a late-breaking session of the 2026 European Hematology Association Congress. In the ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion.<br><br>At the higher dose level, the therapy demonstrated a 100% objective response rate and an 83.3% complete response rate among evaluable patients, with all responses ongoing at the time of data analysis.<br><br>LB2501 also exhibited a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-14 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Genscript Biotech</b> (<b>ASX: 01548</b>) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br><br>The data were presented at a late-breaking session of the 2026 European Hematology Association Congress. In the ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion.<br><br>At the higher dose level, the therapy demonstrated a 100% objective response rate and an 83.3% complete response rate among evaluable patients, with all responses ongoing at the time of data analysis.<br><br>LB2501 also exhibited a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1133005411","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133005411","pubTimestamp":1781432420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Genscript Biotech (ASX: 01548) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1583":"高瓴概念","BK4022":"陆运","01548":"金斯瑞生物科技","BK4230":"旅客陆运","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1141":"生命科学工具和服务","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","CAR":"安飞士"},"translate_title":"金斯瑞生物技术子公司报告淋巴瘤新型体内双靶点CAR-T疗法的概念验证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1,"01548":1},"content_text":"Genscript Biotech (ASX: 01548) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.The data were presented at a late-breaking session of the 2026 European Hematology Association Congress. In the ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion.At the higher dose level, the therapy demonstrated a 100% objective response rate and an 83.3% complete response rate among evaluable patients, with all responses ongoing at the time of data analysis.LB2501 also exhibited a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133005411","isCrawlerRequest":true}